Harrison AI News: Harrison.Rad 1.5 and 2026 Updates
Harrison AI News: Harrison.Rad 1.5 and 2026 Updates
Harrison AI news in 2026 has centered on Harrison.Rad 1.5, new hospital deployments, additional regulatory clearances, and continued expansion of Harrison.ai’s medical imaging platform.
The company’s biggest technical update this year is Harrison.Rad 1.5, a radiology-specific foundation model released in June 2026 for research use. Harrison.ai says the model can work with images, prior studies, and clinical context to help produce draft radiology reports for review.
Latest Harrison AI news at a glance
- Harrison.Rad 1.5 launched on June 9, 2026 for research access.
- The company says the model was trained on about 6 million medical imaging studies.
- Harrison.ai announced FDA 510(k) clearance in March 2026 for acute infarct triage on non-contrast CT brain.
- New deployments were announced in Indonesia and other markets.
- Harrison.ai’s Open Platform added additional third-party AI partners in March 2026.
Harrison.Rad 1.5 is the main 2026 product update
Harrison.ai launched Harrison.Rad 1.5 on June 9, 2026. The company describes it as a multimodal radiology foundation model designed to reason across medical images and text, including prior studies and clinical context.
According to Harrison.ai, the model can produce structured or unstructured draft reports for research workflows. The company also says the training dataset expanded to approximately 6 million medical imaging studies, about one-third larger than the previous version.
Harrison.ai clearly states that Harrison.Rad 1.5 has not been cleared for clinical use. It is a research model and should not be treated as a replacement for professional clinical judgment.
What did Harrison.ai report about performance?
Harrison.ai published benchmark results comparing Harrison.Rad 1.5 with several radiology-specific and general-purpose AI models. The company says its model passed a mock examination styled after the FRCR 2B Short Case format.
These results are useful, but they need context. A benchmark measures performance on a defined test. It does not automatically prove the same level of performance across every hospital, patient population, scanner, or workflow.
Readers interested in how specialised systems differ from general AI tools can also see our best AI tools in 2026 guide.
FDA clearance for acute infarct triage
On March 5, 2026, Harrison.ai announced FDA 510(k) clearance for acute infarct triage on non-contrast CT brain. The company said this became its ninth FDA clearance, covering 13 radiological findings in total.
This cleared product is different from the Harrison.Rad 1.5 research model. That distinction matters because a research foundation model and a regulated clinical product do not have the same intended use, evidence requirements, or authorization status.
Hospital deployments continued to expand
Harrison.ai also announced additional deployments in 2026. In April, the company said its chest X-ray and CT brain support solutions would be rolled out across the Kasih Ibu Hospital Group in Bali, Indonesia.
The company has highlighted adoption across multiple regions, including Australia, the United Kingdom, the United States, and Asia. Deployment announcements show real-world use, but they should still be read separately from independent outcome studies.
Harrison.ai Open Platform added more partners
In March 2026, Harrison.ai announced that four additional AI companies were joining its Open Platform. The platform is designed to give healthcare organizations access to multiple medical imaging AI tools rather than requiring a single-vendor setup.
This approach may be useful because radiology departments often need different tools for X-ray, CT, MRI, mammography, and ultrasound workflows.
How to read Harrison AI news responsibly
Medical AI stories can mix different types of evidence together. A strong benchmark result, a regulatory clearance, and a hospital deployment are not interchangeable.
| Type of evidence | What it tells you |
|---|---|
| Benchmark result | How a model performed on a defined evaluation. |
| Regulatory clearance | Whether a specific product has authorization for a defined use. |
| Hospital deployment | Whether a healthcare organization has implemented the technology. |
| Company announcement | The vendor’s own description of a product, result, or partnership. |
Keeping those categories separate makes it easier to judge what a headline really means.
What to watch next
- Independent evaluation of Harrison.Rad 1.5.
- More peer-reviewed evidence around clinical deployments.
- Additional regulatory clearances in major markets.
- Expansion of the Harrison.ai Open Platform ecosystem.
- Evidence showing how AI affects reporting time, workflow, and patient care in real deployments.
For broader background on AI reliability and evaluation, see our AI system alignment issues guide.
Frequently Asked Questions
Is Harrison.Rad 1.5 approved for clinical use?
No. Harrison.ai says Harrison.Rad 1.5 is available for research and has not been cleared as a clinical medical device.
Does Harrison.ai have FDA-cleared products?
Yes. Harrison.ai has announced multiple FDA clearances for specific radiology products, including acute infarct triage on non-contrast CT brain in March 2026.
Is Harrison.ai only active in Australia?
No. The company has announced deployments and partnerships across several countries and regions.
Bottom line
The main Harrison AI news in 2026 is the launch of Harrison.Rad 1.5 alongside continued regulatory and international expansion of the company’s clinical imaging products.
The most important detail is to distinguish research models from regulated tools. Harrison.Rad 1.5 is presented as a research foundation model, while Harrison.ai’s cleared clinical products have separate intended uses and regulatory status.
For a company-level overview separate from the latest updates, read our Harrison AI company and products guide.
Sources consulted
- Harrison.ai Newsroom and Resources, reviewed September 2026.
- Harrison.ai announcement for Harrison.Rad 1.5, June 9, 2026.
- Harrison.ai FDA clearance announcement, March 5, 2026.
- Harrison.ai Kasih Ibu Hospitals announcement, April 23, 2026.
Editorial transparency: Medical AI products and regulatory status can change. This article separates company-reported research results from regulatory clearances and real-world deployment announcements. It is informational and not medical advice.
